EUCTR2010-021255-81-DE进行中（未招募）不适用
Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in healthy young female volunteers over a period of 3 treatment cycles - Inhibition of ovulation and pharmacokinetic study of 3 transdermal EE and GSD formulations
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 174
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Healthy female subject
- •2.Age: 18 to 35 years (inclusive) at the first screening visit
- •3.Body mass index (BMI): = 18 kg/m²
- •4.Ability to understand and follow study-related instructions
- •5.Willingness to use non-hormonal methods of contraception during the entire study
- •6.Signed informed consent before any study specific tests or procedures are done
- •7.Confirmation of the subject’s health insurance coverage prior to the first screening examination
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal
- •2.Known or suspected malignant tumors (including after treatment)
- •3.Known or suspected benign tumors of the liver, pituitary and adrenal gland (including after treatment)
- •4.Known or suspected liver disorders, including disturbances of bilirubin metabolism (e.g. Dubin-Johnson and Rotor syndromes) and bile secretion/flow (cholestasis, also history of it)
- •5.Conditions/diseases known to occur or deteriorate with both pregnancy and COC use.
- •6.Presence or history of pancreatitis
- •7.Presence or history of venous or arterial thrombotic/thromboembolic events (e.g. deep vein thrombosis, pulmonary embolism, myocardial infarction) or of a cerebrovascular accident, including prodromi (e.g. transient ischaemic attack, angina pectoris) and conditions that could increase the risk to suffer from any of the above mentioned disorders, e.g. a family history indicating hereditary predisposition
- •8.Diseases associated with adverse vascular events (e.g. diabetes mellitus, chronic inflammatory diseases like Crohn’s disease or colitis ulcerosa, severe disorders of lipid metabolism, sickle-cell anemia)
- •9.Severe renal insufficiency or acute renal failure
- •14.Skin diseases with suspected alteration of dermal resorption and/or increased risk for dermal intolerance (e.g. psoriasis, neurodermitis, urticaria)
- •16.Regular use of medicines other than contraceptives
- •17.Use of systemic or topical medicines or substances which oppose the study objectives or which might influence them within 4 weeks before the first study drug administration
- •18.Use of sex hormones (oral, transdermal, intravaginal) during the cycle preceding the pre-treatment cycle
- •19.Use of any long-acting injectable or implant hormonal therapy within 40 weeks prior to the first study drug administration
- •20.Use of an intra-uterine system (IUS) releasing hormones during the cycle preceding the pre-treatment cycle (non-hormonal intra-uterine devices are acceptable)
- •22.Smokers: at the age of 18 to 30 years inclusive (at first screening visit) with a daily consumption of > 10 cigarettes or at the age of 31 to 35 years inclusive (at first screening visit); former smokers who have stopped smoking at least 3 months prior to the first screening visit may be included
- •23.Donation of blood or plasmapheresis after signing the informed consent
- •24.Systolic blood pressure below 90 or above 140 mmHg (after at least 3 min in sitting position)
- •25.Diastolic blood pressure below 45 or above 90 mmHg (after at least 3 min in sitting position)
- •27.Clinically relevant findings in the physical examination (e.g. pronounced varicosis, thrombophlebitis, evidence of peripheral circulatory disturbances, skin abnormalities in the application area)
- •28.Clinically relevant findings in the gynecological examination including transvaginal ultrasound
- •29.Cervical cytological smear classified higher than II according to Papanicolaou (grading I - V)
- •30.Genital bleeding of unknown origin
- •31.Menstrual disorders suspicious of ovarian failure (e.g. oligomenorrhea, amenorrhea, hypomenorrhea)
- •32.Delivery, abortion or lactation less than 3 months before the first screening examination
- •33.Positive urine pregnancy test
- •34.Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), human immune deficiency virus antibodies (anti-HIV 1+2
研究者
相似试验
已完成
2 期
Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in healthy young female volunteers over a period of 3 treatment cyclescontraceptionFertility controlNL-OMON34076Bayer110
进行中（未招募）
不适用
Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in healthy young female volunteers over a period of 3 treatment cycles - Inhibition of ovulation and pharmacokinetic study of 3 transdermal EE and GSD formulationsPrevention of PregnancyMedDRA version: 12.1Level: LLTClassification code 10060346Term: Transdermal contraceptionEUCTR2010-021255-81-NLBayer HealthCare AG174
进行中（未招募）
不适用
Multicenter, open-label, randomized study to evaluate inhibition of ovulation of two transdermal patch formulations containing 0.55 mg ethinylestradiol and either 1.05 or 2.1 mg gestodene in healthy young female volunteers over a period of 3 treatment cycles - Inhibition of ovulation and pharmacokinetics of transdermal EE and GSDThe trial will be performed in healthy female volunteers. The intended indication is femal contraception.EUCTR2009-009177-10-DEBayer HealthCare AG
进行中（未招募）
1 期
Multicenter, randomized, open-label study to evaluate the efficacy and safety of SOC + Sarilumab versus Standard of Care for the Early Treatment of COVID-19-pneumonia in Hospitalized PatientsEUCTR2020-002037-15-ESCristina Avendaño Sola200
进行中（未招募）
1 期
Multi-center, open-label, randomized study to assess the safety and contraceptive efficacy of two doses (in vitro 12 µg/24 h and 16 µg/24 h) of the ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) for a maximum of 3 years in women 18 to 35 years of age - LCS Pearl Index StudyContraceptionMedDRA version: 9.1Level: PTClassification code 10010808Term: ContraceptionEUCTR2007-000420-40-FRBayer Schering Pharma Oy